公开(公告)号：US20230115867A1

公开(公告)日：2023-04-13

申请号：US18072752

申请日：2022-12-01

Applicant: Kowa Company, Ltd.

Inventor： Ryu OSHIMA ,  Masatoshi ITO ,  Chisato NAGAI

IPC: A61K31/423 ,  A61K31/34 ,  A61K31/4152 ,  A61K31/427 ,  A61K31/4353 ,  A61K31/4402 ,  A61K31/4433 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7034 ,  A61K38/13 ,  A61P3/06 ,  A61K31/7048

Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereitiafter also referred to as pemafiterate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pernafiterate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

公开(公告)号：US20220296588A1

公开(公告)日：2022-09-22

申请号：US17708706

申请日：2022-03-30

Applicant: Kowa Company, Ltd.

Inventor： Ryu OSHIMA ,  Masatoshi ITO ,  Chisato NAGAI

IPC: A61K31/496 ,  A61K38/13

Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy).
A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

公开(公告)号：US11446282B2

公开(公告)日：2022-09-20

申请号：US16726857

申请日：2019-12-25

Applicant: Kowa Company, Ltd.

Inventor： Ryu Oshima ,  Kazuhito Suehira ,  Gary Gordon

IPC: A61K31/423 ,  A61P3/06

Abstract: The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.

公开(公告)号：US11419855B2

公开(公告)日：2022-08-23

申请号：US16627058

申请日：2018-06-29

Applicant: KOWA COMPANY, LTD.

Inventor： Shin Sugimoto ,  Akito Minamizono

IPC: A61K31/423 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K47/38

Abstract: Provided is a novel technique for improving storage stability of a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and a cellulose species. A pharmaceutical preparation obtained by storing a pharmaceutical composition containing the following components (A) and (B) in a tight package: (A) pemafibrate, a salt thereof or a solvate thereof; and (B) a cellulose species.

公开(公告)号：US20220257627A1

公开(公告)日：2022-08-18

申请号：US17708740

申请日：2022-03-30

Applicant: Kowa Company, Ltd.

Inventor： Ryu OSHIMA ,  Masatoshi ITO ,  Chisato NAGAI

IPC: A61K31/7048 ,  A61K31/423 ,  A61P3/06

Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy).
A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

公开(公告)号：US11369264B2

公开(公告)日：2022-06-28

申请号：US16637210

申请日：2018-08-09

Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  KOWA COMPANY, LTD.

Inventor： Norihiko Yokoi ,  Yuka Sugiura ,  Katsumi Yabusaki

IPC: A61B3/10 ,  G06T7/136 ,  G06T7/13 ,  G06T7/00

Abstract: A method for dynamically evaluating a tear fluid layer using an interference fringe image of the tear fluid layer composed of a plurality of consecutive frames, and includes: an image creation step of creating at least one break detection image of a first break detection image, a second break detection image, a third break detection image, and a fourth break detection image, which are images for detecting a breaking site of the tear fluid layer; a determination step of determining whether the break detection image created by the image creation step corresponds to a predetermined breakup pattern; a tally step of tallying the determination results determined by the determination step; and an evaluation step of evaluating, on the basis of a tallied result by the tally step, a breakup pattern of the interference fringe image of the tear fluid layer.

公开(公告)号：US11344535B2

公开(公告)日：2022-05-31

申请号：US16627061

申请日：2018-06-29

Applicant: KOWA COMPANY, LTD.

Inventor： Yuki Kuroiwa ,  Akito Minamizono

IPC: A61K31/423 ,  A61K9/14 ,  A61K9/20 ,  A61K9/48

Abstract: Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent storage stability. The pharmaceutical composition is provided to contain pemafibrate, a salt thereof or a solvate thereof, wherein a pH value of a solution produced by dissolving or dispersing the pharmaceutical composition in water is 7 or more.

公开(公告)号：US11266308B2

公开(公告)日：2022-03-08

申请号：US16306398

申请日：2017-05-29

Applicant: KOWA COMPANY, LTD.

Inventor： Katsumi Yabusaki

IPC: A61B6/00 ,  A61B5/05 ,  A61B3/00 ,  A61B3/14 ,  A61B3/10

Abstract: Provided are a method and a device for evaluating a tear fluid to objectively evaluate and determine the severity of dry eye or the like. Color information is acquired in a predetermined region of a tear fluid interference fringe image, a numerical value representing a color diversity is calculated from the color information acquired, and the numerical value representing the color diversity thus calculated is used as an index for evaluating a tear fluid state.

公开(公告)号：US11020219B2

公开(公告)日：2021-06-01

申请号：US16424051

申请日：2019-05-28

Applicant: KOWA COMPANY, LTD.

Inventor： Asaki Suzaki

IPC: A61F2/16 ,  B29D11/00 ,  B29D11/02 ,  G02C7/02

Abstract: Provided is an intraocular lens having a novel structure with high utility which is easy to adapt to patients, and can improve quality of vision (QOV). In an intraocular lens, an optical characteristic is set rotationally symmetric around an optical axis, and a spherical aberration of a size corresponding to a coma aberration remaining in a patient's eye after extraction of a human lens of the eye is set.

公开(公告)号：US20210069158A1

公开(公告)日：2021-03-11

申请号：US17099366

申请日：2020-11-16

Applicant: Kowa Company, Ltd.

Inventor： Ryu Oshima ,  Gary Gordon

IPC: A61K31/423 ,  A61K31/41 ,  A61K9/00 ,  A61K31/366 ,  A61K31/40 ,  A61K31/47 ,  A61K31/505 ,  A61K45/06

Abstract: The present invention relates to pharmacological interventions with pemafibrate for cardiovascular diseases and adverse cardiovascular events. In addition, the invention relates to the use of pemafibrate to treat dyslipidemia and type 2 diabetes mellitus and thereby reduce the risk of cardiovascular disease and adverse cardiovascular events.